Bern-based Rhovica Neuroimaging AG has raised CHF 2.3 million in a financing round led by M2care, with participation from Kickfund, Valuemaker and several other business angels. The funding will accelerate the development of SoNav, Rhovica’s bedside navigation system for life-saving drainage catheters used in emergency neurosurgery..

伯尔尼的罗维卡神经影像公司（Rhovica Neuroimaging AG）在由M2care领投、Kickfund、Valuemaker及多位其他商业天使参与的一轮融资中筹集了230万瑞士法郎。这笔资金将加速推动罗维卡用于紧急神经外科手术中的救命引流导管的床旁导航系统SoNav的开发。

Rhovica Neuroimaging AG

罗维卡神经影像股份公司

, founded in 2023 by neurosurgeons Martin Hlavica and Thomas Rhomberg, is pioneering solutions to improve emergency treatment for patients with life-threatening increased brain pressure. One of the most common procedures in such cases is the placement of an external ventricular drain (EVD) for example after severe trauma or intracranial bleeding.

，由神经外科医生马丁·赫拉维卡 (Martin Hlavica) 和托马斯·罗姆伯格 (Thomas Rhomberg) 于 2023 年创立，致力于开创改善危及生命的颅内高压患者紧急治疗的解决方案。在这些情况下，最常见的程序之一是放置外脑室引流管 (EVD)，例如在严重创伤或颅内出血之后。

Today, this is often performed freehand at the bedside—fast but imprecise—or with navigation systems in the operating room, which delays urgent care. This trade‑off between speed and accuracy can worsen patient outcomes..

今天，这通常在床边徒手进行——快速但不精确——或在手术室中使用导航系统，但这会延误紧急护理。速度与精度之间的这种权衡可能会导致患者预后恶化。

Rhovica’s SoNav system addresses this challenge with integrated sensors that provide real‑time visualization for guided catheter insertion directly at the bedside. The technology will also enable continuous monitoring of brain ventricles, reducing repeated CT scans, improving safety and outcomes, and lowering costs.

Rhovica的SoNav系统通过集成传感器解决了这一挑战，这些传感器可提供实时可视化，用于在床边直接引导导管插入。该技术还将实现对脑室的持续监测，减少重复的CT扫描，提高安全性和治疗效果，并降低成本。

With this approach, the company positions itself in the growing neurosurgical device market environment, which is expected to grow between 4.5% and 14.2% in the coming years..

通过这一方法，该公司在不断增长的神经外科设备市场环境中定位自身，预计未来几年该市场将增长4.5%至14.2%。

The financing round was led by

本轮融资由

M2care

M2care

, alongside Swiss investment firms

，以及瑞士投资公司

Kickfund

踢基金

, and

，以及

Valuemaker

价值创造者

, as well as several business angels. Together, they bring strong medtech expertise and networks that will support Rhovica in its next phase of development.

，以及多位商业天使投资人。他们共同带来了强大的医疗技术专业知识和人脉网络，将支持 Rhovica 进入下一阶段的发展。

Martin Hlavica, CEO and Co-founder of Rhovica, stated: “This fundraising marks an important milestone for Rhovica. The trust of our investors strengthens our ability to advance the development of SoNav and move closer to making this solution available to patients in need.”

马丁·赫拉维卡（Martin Hlavica），Rhovica的首席执行官兼联合创始人表示：“此次融资标志着Rhovica的一个重要里程碑。投资者的信任增强了我们推进SoNav开发的能力，并让我们更接近于将这一解决方案提供给有需要的患者。”

Florence Thueux, President of M2care, commented: “M2care combines investment capacity with hands-on expertise to de-risk early healthtech ventures to Series-A readiness. Rhovica reflects this approach: addressing a clear clinical need with a strong team and a technology that can transform emergency neurosurgery.

弗洛伦斯·特欧，M2care总裁评论道：“M2care将投资能力与实际操作的专业知识相结合，为早期健康科技企业降低风险，助其达到A轮融资的成熟度。Rhovica正体现了这一方法：以强大的团队和能够变革急诊神经外科的技术，解决明确的临床需求。”

We are proud to actively support the company in this next phase of development.” M2care is a European venture studio created by Mérieux Développement and CEA Investissement, specializing in healthtech. .

我们很自豪能够在公司发展的下一阶段积极提供支持。M2care 是由 Mérieux Développement 和 CEA Investissement 创建的欧洲风险投资工作室，专注于健康科技。

To further strengthen its development, Rhovica has appointed

为了进一步加强其发展，Rhovica任命了

Carsten Laue

卡斯滕·劳厄

, Managing Director at M2care, to its Board of Directors. His expertise in medtech strategy and company building will support the company in advancing SoNav toward clinical adoption.

M2care的董事总经理，进入董事会。他在医疗技术战略和公司建设方面的专业知识将支持公司推动SoNav走向临床应用。

Carsten Laue added: “By joining Rhovica’s board, I look forward to actively supporting the team in translating a strong clinical need into a viable medtech solution. The project’s origin in emergency neurosurgical care, combined with the founders’ complementary expertise, reflects precisely the type of innovation that M2care is set up to accelerate.”.

卡斯滕·劳厄补充道：“通过加入Rhovica的董事会，我期待积极支持团队将强烈的临床需求转化为可行的医疗技术解决方案。该项目起源于急诊神经外科护理，结合了创始人们互补的专业知识，正是M2care旨在加速推动的创新类型。”

(Press release / SK)

（新闻稿 / SK）

0

0

Comments

评论

Back to all news

返回所有新闻

Please

请

login

登录

or

或

sign up

注册

to comment.

评论。

Commenting guidelines

评论指南

Send

发送